HSBC upgraded shares of DiaSorin (OTCMKTS:DSRLF – Get Rating) from a hold rating to a buy rating in a report published on Tuesday morning, The Fly reports.
DSRLF has been the subject of several other research reports. Stifel Nicolaus initiated coverage on DiaSorin in a report on Tuesday, November 29th. They issued a hold rating for the company. Berenberg Bank cut their price target on DiaSorin from €170.00 ($180.85) to €153.00 ($162.77) in a report on Tuesday, November 8th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Hold and a consensus target price of $143.00.
DiaSorin Price Performance
DiaSorin stock opened at $132.90 on Tuesday. The business has a 50 day moving average price of $133.52 and a two-hundred day moving average price of $128.94. DiaSorin has a 12 month low of $107.00 and a 12 month high of $175.20.
DiaSorin Company Profile
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The firm specializes in the immunodiagnostics and molecular diagnostics segments. It provides clinical services in the areas like Infectious Diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Stool Diagnostics and Autoimmunity.
- Get a free copy of the StockNews.com research report on DiaSorin (DSRLF)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.